Taking the question as asked, rather than the general version of it. A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.
Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.
The bit I cannot resolve on my own is whether an unchanged LDL-C alongside a large triglyceride fall is a good result or a bad one, because ApoB and LDL-C seem to be telling different stories.
Not looking for reassurance. Looking for the part I have got wrong.
BethLabQueen said:A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin…
Agreed, and reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.
PeptideMeter — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsLipidDoc_ATL said:Trying to work out whether my panel improved or merely rearranged itself, because two of the numbers went the wrong way.
Can confirm the pattern LipidDoc_ATL describes. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.
From the other side of the consultation, briefly.
Omega-3 index improvement on the lipid panel: often overlooked but my omega-3 index went from 4.2% to 8.2% over 9 months. I supplemented with 2g EPA+DHA daily.
This matters because omega-3s are anti-inflammatory and cardioprotective, complementing the GLP-1 benefits. Target omega-3 index is >8%. Combined with the triglyceride reduction from the medication, my lipid profile is the best it's been in decades.